European Medical Information Framework (EMIF)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • Disease focus:
    Alzheimer's Disease, Obesity, Type 1 Diabetes

Abstract

The European Medical Information Framework (EMIF) project aims to develop a common information framework of patient-level data that will link and facilitate access to diverse medical and research data sources, opening up new avenues of research for scientists. To provide a focus and guidance for the development of the framework, the project will focus initially on questions relating to obesity and Alzheimer’s disease (AD).

Mission

EMIF’s mission is to improve access to human health data, thus enabling new insights into diseases and treatments. As part of the broader European Innovative Medicines Initiative (IMI), EMIF aims to create an environment that allows for efficient reuse of existing health data. A common information framework (EMIF-Platform) will link and facilitate access to diverse medical and research data sources. The project’s main objective is to create an environment that allows for efficient reuse of existing health data.

To ensure immediate applicability, the EMIF project includes two specific therapeutic research topics: the onset of AD (EMIF-AD) and metabolic complications of obesity (EMIF-Metabolics). The AD topic aims to discover and validate biomarkers of AD onset in the preclinical and prodromal phases as well as study disease progression and identify high-risk individuals for therapeutic trials for prevention. The Metabolic topic aims to discover and evaluate biomarkers for the risk of metabolic complications in obesity and to identify high-risk populations for intervention purposes. Collaboration between the two topics will ensure the development and delivery of an efficient information framework.

Consortium History

2013: Start date

Structure & Governance

The Operations Team is concerned with the day-to-day aspects of the project and consists of the following members:

Bart Vannieuwenhuyse, coordinator, EMIF
Janssen Pharmaceutica NV

Carlos Diaz, overall project manager
Synapse Research Management Partners S.L

Johan van der Lei, managing entity
Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, The Netherlands

Simon Lovestone, co-coordinator, EMIF
University of Oxford, Oxford, United Kingdom

Ulf Smith, topic lead, EMIF-Metabolics
Göteborgs Universitet

The Program Board will define the strategic focus of the overall project, manage the overall integration of the three topics, and ensure that the overall objectives of EMIF are delivered. As such, it will provide a cross-topic forum for further in-depth scientific debate of cross-topic issues to ensure synergy and optimization of the overall project. The members include the operations team members and the following individuals:

Dawn Waterworth, European Federation of Pharmaceutical Industries and Associations (EFPIA) lead, EMIF-Metabolics
GlaxoSmithKline

Dipak Kalra, representative, EMIF-Platform
University College London

Mike Krams, EFPIA lead, EMIF-AD
Janssen Pharmaceutica NV

Patrick Genyn, EFPIA lead, EMIF-Platform
Janssen Pharmaceutica NV

Pieter Deurinck, representative, EMIF-Platform
UCB

Pieter-Jelle Visser, topic lead, EMIF-AD
VU Medical Center Amsterdam

Ulf Smith, topic lead, EMIF-Metabolics
Göteborgs Universitet

The Project Management Office (PMO) will support the successful implementation of this project on the scientific, financial, and management levels. As such, it will provide integral support to the coordinator and managing entity on all the aspects of project management, including financial, legal, risk, and knowledge management, internal and external communication, and administrative and reporting issues. The members of the PMO are as follows:

Ameli Schwalber, project manager, EMIF-AD
Concentris Research Management GmbH

Angel Honrado, project manager, EMIF-Platform
Synapse Research Management Partners S.L

Bart Vannieuwenhuyse, coordinator, EMIF
Janssen Pharmaceutica NV

Carlos Diaz, overall project manager
Synapse Research Management Partners S.L

Caroline Sage, project manager, EMIF-PMO
Janssen Pharmaceutica NV

Els Veldeman, project manager, EMIF-Platform
Janssen Pharmaceutica NV

Eva Molero, project manager, EMIF-Platform
Synapse Research Management Partners S.L

Graham Somers, project manager, EMIF-Metabolics
GlaxoSmithKline

Martha C. Chapelsky, project manager, EMIF-Metabolics
GlaxoSmithKline

Moritz Eckert, project manager, EMIF-AD
Concentris Research Management GmbH

Sandra Pla, project manager, EMIF-Platform
Synapse Research Management Partners S.L

The General Assembly will function as a forum for general project follow-up, awareness on the project status, and internal communication. The General Assembly is responsible for decisions that according to the grant agreement must be made by all partners.

EMIF will engage three separate Scientific Advisory Boards (SABs), one for each of the three topics. The SABs include experts nominated by the respective consortia to provide advice about the corresponding topic. Each year, there will be a joint meeting of the three SABs and the Program Board to discuss project progress. The boards are as follows:

Scientific Advisory Board, EMIF-Platform

Financing

EMIF receives support from the IMI Joint Undertaking (JU) under grant agreement no. 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and the EFPIA in kind contribution. The IMI has contributed €24.4 million, the EFPIA has contributed €24.1 million in kind, and other sources have contributed €7.9 million, for a total cost of €56.4 million. 

Intellectual Property

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI JU.  To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at the following address: http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

Data Sharing

According to IMI’s IP policy, the participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The project agreement shall include a description of the material, which must be disseminated in accordance with the IP policy and referenced in the grant agreement. If the participants do not disseminate within such time periods without good reason, then the Executive Office has the right to disseminate such results in a manner consistent with the grant agreement.

In 2013, four papers were published on behalf of EMIF. The list of publications can be accessed at http://www.emif.eu/emif/scientific-publications/publications

Points of Contact

Bart Vannieuwenhuyse
Janssen Pharmaceutica NV
phone: +32 14 600320
email: bvannieu@its.jnj.com

Simon Lovestone
King’s College London
phone: +44 20 7848 0239
email: simon.lovestone@kcl.ac.uk

Johan van der Lei
Erasmus Universitair
Medisch Centrum Rotterdam
phone: +31 10 70 441 22
email: j.vanderlei@erasmusmc.nl

Sponsors & Partners

Aarhus Universitets hospital, Aarhus Sygehus

Agenzia Regionale di Sanita

Alzheimer Europe

Amgen NV

Assistance Publique - Hôpitaux de Paris

Boehringer Ingelheim International GmbH

Brighton Collaboration Foundation

Cambridge Cognition Ltd.

Concentris Research Management GmbH

Custodix NV

Ealing Hospital NHS Trust

Electrophoretics Ltd.

Erasmus Universitair Medisch Centrum Rotterdam

European Institute for Health Records

European Molecular Biology Laboratory

F. Hoffmann-La Roche AG, Basel

Fondazione PENTA - for the Treatment and Care of Children with HIV-ONLUS

GENOMEDICS S.R.L.

GlaxoSmithKline Research & Development Ltd.

Göteborgs Universitet

Helsingin Yliopisto

Institut de Recherches Internationales Servier

Institut für Epidemiologie und Präventionsforschung GmbH

Institut National de la Santé et de la Recherche Médicale

Itä-Suomen Yliopisto

Janssen Pharmaceutica NV

Karolinska Institutet

King’s College London

Maastricht University

MAAT France

Max-Planck-Gesellschaft zur Förderung der Wissenschaften

Novo Nordisk

Pfizer Ltd.

Pharmo Cooperatie UA

Provincia Lombardo-Veneta - Ordine Ospedaliero di San Giovanni di Dio

Societa Servizi Telematici SRL

Synapse Research Management Partners S.L.

Tartu Ulikool

Teknologian tutkimuskeskus VTT

UCB Pharma SA

Universidade de Aveiro

Università degli Studi di Pisa

Universität Leipzig

Universitat Pompeu Fabra

Universitätsklinikum Erlangen, Anstalt des Öffentlichen Rechts

Universiteit Antwerpen

University College London

University of Cambridge

University of Copenhagen

University of Eastern Finland

University of Glasgow

University of Leicester

University of Manchester

University Pierre et Marie Curie

Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek en Patiëntenzorg

VIB

VU University Medical centre Amsterdam


Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.